Evidence map›Paper›PMID 39545737›Full record

ArticleAntimicrobial agents and chemotherapy2024

The extended recovery ring-stage survival assay is a scalable alternative for artemisinin susceptibility phenotyping of fresh

Martin Okitwi, Douglas A Shoue, Lisa A Checkley, Stephen Orena, Frida G Ceja, Yoweri Taremwa, Patrick K Tumwebaze, Thomas Katairo, Oswald Byaruhanga, Mackenzie A C Sievert and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Martin OkitwiInfectious Diseases Research Collaboration, Kampala, Uganda.
Douglas A ShoueDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.ORCID 0000-0003-4991-6039
Lisa A CheckleyDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.ORCID 0000-0003-2442-0301
Stephen OrenaInfectious Diseases Research Collaboration, Kampala, Uganda.
Frida G CejaDominican University of California, San Rafael, California, USA.
Yoweri TaremwaInfectious Diseases Research Collaboration, Kampala, Uganda.
Patrick K TumwebazeInfectious Diseases Research Collaboration, Kampala, Uganda.
Thomas KatairoInfectious Diseases Research Collaboration, Kampala, Uganda.
Oswald ByaruhangaInfectious Diseases Research Collaboration, Kampala, Uganda.
Mackenzie A C SievertDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.
Shreeya GargUniversity of California, San Francisco, California, USA.
Oriana K KreutzfeldUniversity of California, San Francisco, California, USA.ORCID 0000-0003-2026-345X
Jennifer LegacUniversity of California, San Francisco, California, USA.
Jeffrey A BaileyBrown University, Providence, Rhode Island, USA.
Sam L NsobyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Melissa D ConradUniversity of California, San Francisco, California, USA.ORCID 0000-0002-9984-8030
Philip J RosenthalUniversity of California, San Francisco, California, USA.ORCID 0000-0002-7953-7622
Michael T FerdigDepartment of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, Indiana, USA.ORCID 0000-0003-3516-9829
Roland A CooperDominican University of California, San Rafael, California, USA.ORCID 0000-0002-8437-9382

Funding

Systems genetics of artemisinin resistanceP01AI127338 · NIAID · UNIVERSITY OF NOTRE DAME · PI Michael T Ferdig · 2017 to 2026
$21.3M
Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipelineR01AI139179 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Philip Jon Rosenthal · 2018 to 2026
$6.3M
Surveillance to track and characterize antimalarial resistance trends in Ugandan Plasmodium falciparum parasites (STARTUP)R01AI173557 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Melissa D Conrad · 2023 to 2026
$2.9M
Resistance of Malaria Parasites to Artemisinin-Based Combination TherapiesR56AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2008 to 2008
$618k
Gates Foundation INV-035751HHS | National Institutes of Health (NIH) AI075045, AI139179HHS | National Institutes of Health (NIH) AI127338HHS | National Institutes of Health (NIH) AI173557NIAID NIH HHS P01 AI127338NIAID NIH HHS R01 AI075045NIAID NIH HHS R01 AI139179NIAID NIH HHS R01 AI173557NIAID NIH HHS R56 AI075045
6 · The paper itself

Abstract

Artemisinin partial resistance (ART-R) has emerged in eastern Africa, necessitating regular surveillance of susceptibility of

Indexed as

AntimalarialsArtemisininsDrug ResistanceMalaria, FalciparumParasitic Sensitivity TestsPlasmodium falciparumHumansInhibitory Concentration 50UgandaAntimalarialsartemisininArtemisininsartenimolartemisinin partial resistancemalariaPlasmodium falciparumring-stage survival assay

Identifiers

PMID39545737
PMCPMC11619366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.